Opinion

Published within

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Bayer: the end of an era?

Published By Datamonitor
15 Aug 2001
CommentWire
CommentWire

Bayer: seeking Gamunex approval

Bayer has filed for approval for its immune globulin intravenous drug, Gamunex. It's a purer alternative to Bayer's existing Gamimune; its major indication is primary immunodeficiency. For Gamunex to be a major success, Bayer will need to convince healthcare payors that its lower risk of associated infection makes it more cost-effective than its stablemate.

Published By Datamonitor
10 Sep 2002
CommentWire
CommentWire

Bayer: sales growth from Schering but future focus on Nexavar

Bayer Schering has reported robust second quarter sales, and an overall positive performance during the first half of the year, boosted by strong product lines such as Yasmin and Betaferon which were gained from the acquisition of Schering AG in 2006. However, the leading German pharmaceutical company's future focus relies heavily on the new oncology treatment Nexavar.

Published By Datamonitor
08 Aug 2007
CommentWire
CommentWire

Bayer: Roche not a buyer

Published By Datamonitor
29 Aug 2001
CommentWire
CommentWire

Bayer: rethinking pricing strategies

Published By Datamonitor
19 Sep 2000
CommentWire
CommentWire

Bayer: respiratory divestment signals strategic strengthening

Bayer's [BAY.F] move to spin off non-core R&D projects such as its respiratory pipeline could be seen as further proof of its move away from ethical pharmaceuticals. However, it may be just a strategic decision to enable the company to concentrate on its core product areas as it faces some significant short term challenges.

Published By Datamonitor
26 Aug 2004
CommentWire
CommentWire

Bayer: OTC purchase fails to address bigger picture

Bayer [BAY] is seemingly keen to focus more closely on the low-risk consumer wellbeing sector. Although the acquisition of Roche's [ROCZ.S] OTC operation will boost Bayer's bottom line, it does little to address concerns about its wider pharma portfolio. The move may even signify Bayer's retreat from the ethical pharma business.

Published By Datamonitor
21 Jul 2004
CommentWire
CommentWire

Bayer: more pharmaceutical uncertainty

Published By Datamonitor
13 Sep 2001
CommentWire
CommentWire

Bayer: kidney cancer drug offers hope for patients and pipeline

Results from a Phase II trial have shown BAY 43-9006's antitumor activity in progressive advanced kidney cancer patients, which will support forthcoming Phase III trial results to seek full marketing approval for the drug. The drug could potentially be a source of great promise for Bayer, which is currently suffering from a weak pipeline.

Published By Datamonitor
25 Oct 2004
CommentWire
CommentWire

Bayer: in-licensing required to address decline

As Bayer [BAY.F] restructures, the management needs to take urgent steps to address declining pharmaceutical sales. Bayer would benefit from in-licensing drugs from other companies or creating joint-venture partnerships to address short-term revenue issues. In the long-term, the company should seek to bolster its biotechnology division with increased investment.

Published By Datamonitor
17 Dec 2003

« | ... | 1565 | 1566 | 1567 | 1568 | 1569 | 1570 | 1571 | 1572 | 1573 | ... | » »|

No help is available.